Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by epidermal barrier dysfunction, immune dysregulation, and significant clinical burden. In Mongolia, research on AD has increased over the past decade; however, findings remain fragmented across various areas. Aim: To synthesize evidence from studies conducted in Mongolia over the last 10 years regarding the pathogenesis, clinical features, diagnosis, and treatment of atopic dermatitis. Materials and Methods: A narrative review was conducted, including original studies on Mongolian populations published within the last decade. Studies addressing skin barrier function, immunological mechanisms, genetic factors, environmental exposures, clinical severity, diagnostic tools, and treatment approaches were included. Results: The study findings show that genetic studies identified polymorphisms in the filaggrin gene and, more recently, mutations in the GCDH gene, suggesting these are linked to AD severity and allergen sensitization. Research on the immunopathogenesis of AD revealed that Th2-type cytokines, especially IL-3 and IL-4, are associated with pruritus and disease severity. Additionally, decreased skin hydration and increased transepidermal water loss in individuals with AD were linked to greater disease severity. Disease severity was evaluated using the SCORAD, EASI, and POEM tools, with most studies reporting that mild-to-moderate AD was most common. Clinically, symptoms like pruritus and sleep disturbances were evident. Additionally, clinical severity was associated with laboratory markers, particularly total IgE levels. The high rate of sensitization to inhalant and food allergens suggests that extrinsic atopic dermatitis (AD) may be common in the Mongolian population. In treatment studies using locally relevant natural products in Mongolia, such as seabuckthorn oil and Shargaljuut mineral spring spray, these products were associated with clinical improvement, suggesting they could serve as additional therapeutic options. Conclusion Research on atopic dermatitis in Mongolia has progressed in several areas; however, the current evidence remains limited and is mostly based on cross-sectional, small-sample, single-center, hospital-based studies. Therefore, there is a need for future comprehensive studies that are multicenter, long-term, and involve larger populations.

Background: Linear IgA bullous dermatosis (LABD) is a rare autoimmune blistering disease characterized by linear deposition of immunoglobulin A along the subepidermal basement membrane zone. Although it can occur in both children and adults, the disease in pediatric patients often requires careful consideration due to challenges in differential diagnosis and variability in treatment response. Dapsone is considered the first-line treatment; however, in some cases it may be unavailable, contraindicated, or associated with adverse effects, necessitating alternative therapeutic options. Case Presentation In this case report, we present the clinical features, diagnostic findings, treatment course, and outcomes of a 9-year-old girl diagnosed with LABD. The combination of colchicine and systemic corticosteroids resulted in marked clinical improvement, suggesting that this regimen may be a potential alternative treatment for LABD.